Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 3/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31169448 | 1.00 | CYP11B1 (0.32) | CYP11B1CYP11B2GRIN1GRIN2B | |
| SCHEMBL23601044 | 0.88 | ADORA2A (0.33) | — | |
| SCHEMBL23601045 | 0.85 | CYP11B1 (0.32) | CYP11B1CYP11B2 | |
| SCHEMBL31169401 | 0.85 | CYP11B1 (0.32) | CYP11B1CYP11B2 | |
| SCHEMBL23601064 | 0.83 | CYP1A2 (0.34) | CYP11B1CYP11B2 | |
| SCHEMBL23578530 | 0.83 | ABCG2 (0.33) | CYP11B1CYP11B2GRIN1GRIN2B | |
| SCHEMBL23576707 | 0.80 | CYP11B1 (0.30) | CYP11B1CYP11B2 | |
| SCHEMBL29909172 | 0.78 | — | — | |
| SCHEMBL30979130 | 0.75 | — | — | |
| SCHEMBL23577253 | 0.74 | ALPL (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2022-10-13 | — | — | US | disclosed |
| WO-2021130638-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | CARNA BIOSCIENCES, INC. (JP) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | CYP11B1 4046/4885CYP11B2 4258/4885GRIN1 3148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.